Location History:
- Ledyard, CT (US) (2002 - 2006)
- Essex, CT (US) (2012 - 2013)
Company Filing History:
3 out of 3 
2 out of 19 
1 out of 589 
Years Active: 2002-2013
Title: The Innovative Contributions of Richard P. Gill
Introduction
Richard P. Gill is a notable inventor based in Essex, Connecticut, who has made significant contributions to the field of therapeutic efficiency and biomarker analysis. With a total of nine patents to his name, Gill's work focuses on improving methods for determining the efficacy of therapeutic compounds and screening biomarkers in bodily fluids. His innovative approaches have the potential to enhance medical diagnostics and treatment efficacy.
Latest Patents
Among his latest patents, Gill has developed methods for determining the efficiency of a therapeutic. This method involves treating a subject with a therapeutic compound, harvesting cells, and analyzing them for diagnostic markers. By creating a marker profile and comparing it with previous profiles, the efficacy of the therapeutic compound can be assessed. Additionally, he has patented systems and methods for screening biomarkers in bodily fluids. This system includes a detection platform with multiple sites for diagnostic markers and stabilization agents, allowing for the analysis of binding characteristics between detection agents and diagnostic markers.
Career Highlights
Throughout his career, Richard P. Gill has worked with various companies, including Companion Diagnostics Inc. His innovative work has led to advancements in therapeutic efficacy assessment and biomarker screening, making a significant impact in the medical field.
Collaborations
Gill has collaborated with notable professionals in his field, including Rakesh Vig and Richard H. Selinfreund. These collaborations have contributed to the development of his patented technologies and methodologies.
Conclusion
Richard P. Gill's contributions to the field of therapeutics and biomarker analysis demonstrate his commitment to innovation and improvement in medical diagnostics. His patents reflect a deep understanding of the complexities involved in therapeutic efficacy and the importance of accurate biomarker screening.